Reviving Europe's IPO Market: What VCs Need to Do
Executive Summary
Professor Christopher Evans, DSc, chairman of venture firm Merlin Biosciences, identified European public market investors' continued reluctance to support biotech IPOs as a significant threat to the sector's viability during a keynote presentation at the Financial Times Global Biotech conference in London in November. Yet there's a lot more VCs themselves can do to get the sector back on its feet, acknowledges Merlin's CEO Mark Clement, including putting more money into creating stronger companies from the outset, and simplifying approaches to, and support for, M&A.